Replies to post #133540 on Biotech Values

[NP1986]

You're thinking of ARRY-543, the HER2/EGFR inhibitor, that was licensed to ASLAN (#msg-65133150 ). Tony is referring to ARRY-380, which actually did have some limited PoC in breast cancer patients (#msg-55080837 )

Thanks for the clarification. The HER2 space is getting quite crowded, so that could make finding a partner difficult. The phase I study is too small to characterize the true safety profile of the compound (something like cardiac adverse events would probably only be evident in a larger trial). Do you know if it is a reversible or irreversible inhibitor of HER2?